AstraZeneca says some manufacturing steps moved to Saudi Arabia 3 years ago

23/09/2021 Argaam

AstraZeneca vaccine

Sameh ElFangary, Head of GCC region at AstraZeneca, said that the global COVID-19 vaccine manufacturer kicked off a plan three years ago to move some manufacturing steps to Saudi Arabia, along with investing in the related local infrastructure.

 

In an interview with Al-Arabiya TV, ElFangary said that the recently signed memorandum of understanding (MoU) will boost production cycle, as the company plans to reach 75% of its total products that fulfil the needs of citizens by 2025.

 

AstraZeneca has ambitious plans for the Kingdom, which include establishing a platform for scientific research and clinical trials in Riyadh, specialized in bio-technology and exploring new innovative treatments.

 

The company is currently focused on local content, following which Saudi Arabia will become a distribution hub for the entire region, ElFangary added.

 

According to data compiled by Argaam, AstraZeneca recently signed an MoU the Ministry of Investment and the Ministry of National Guard - Health Affairs (MNG-HA).

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.